Boston Scientific (NYSE:BSX) Price Target Cut to $55.00 by Analysts at Leerink Partners

Key Points

• Leerink Partners lowered Boston Scientific’s price target to $55 from $60, implying roughly 27.75% upside from the stock’s previous close. Analysts overall maintain a “Moderate Buy” consensus with an average target of $68.60.
• Boston Scientific shares rose 0.8% to $43.05, near the lower end of their 52-week range. The company recently exceeded quarterly expectations, reporting $0.86 in adjusted EPS and $5.44 billion in revenue, while guiding to full-year 2026 EPS of $3.28–$3.32.
• Insiders and institutional investors have shown buying interest: insiders purchased 194,522 shares worth approximately $9.4 million over the past quarter, while institutional investors own 89.07% of the company.

Boston Scientific (NYSE:BSX - Get Free Report) had its price target cut by stock analysts at Leerink Partners from $60.00 to $55.00 in a note issued to investors on Friday. Leerink Partners' target price points to a potential upside of 27.75% from the company's previous close.

A number of other equities analysts also recently commented on BSX. Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. Weiss Ratings restated a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $60.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, July 30th. UBS Group decreased their target price on Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Wells Fargo & Company lowered their price target on Boston Scientific from $50.00 to $48.00 and set an "equal weight" rating for the company in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $68.60.

Boston Scientific Stock Up 0.8%

NYSE BSX traded up $0.32 during mid-day trading on Friday, reaching $43.05. 1,663,477 shares of the company's stock traded hands, compared to its average volume of 18,608,648. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific has a 1-year low of $41.38 and a 1-year high of $105.65. The company has a fifty day simple moving average of $46.56 and a 200-day simple moving average of $50.52. The company has a market cap of $62.40 billion, a price-to-earnings ratio of 17.42, a P/E/G ratio of 1.03 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business's revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific will post 3.25 EPS for the current year.

Insiders Place Their Bets

In related news, Director Edward Ludwig bought 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Habiger bought 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company's stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 over the last quarter. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BSX. BlackRock Inc. bought a new position in Boston Scientific in the second quarter worth $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific in the 2nd quarter valued at $2,156,233,000. Janus Henderson Group PLC raised its stake in shares of Boston Scientific by 5.2% in the 4th quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider's stock valued at $1,200,404,000 after buying an additional 617,515 shares in the last quarter. Amundi lifted its holdings in shares of Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock worth $886,213,000 after acquiring an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in Boston Scientific by 25.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock valued at $871,702,000 after acquiring an additional 2,856,040 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.